Purpose: The aim was to explore undefined useful indices for clinically grading adult T-cell leukemia (ATL) using [
Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia

Introduction
Patients with aggressive adult T-cell leukemia (ATL) (i.e. acute, lymphoma and unfavorable chronic types) require intensive treatment, whereas those with indolent ATL (i.e. favorable chronic and smoldering) need mild management as a subtype of chronic lymphoid leukemia [1, 2] . Patients with indolent-type ATL usually exhibit skin lesions and/or leukocytosis with increased levels of abnormal lymphocytes, but show no lymphadenopathy or involvement of organs other than skin or lung. Most patients with indolent ATL are treated with watchful waiting until disease progression to acute crisis. We sometimes find patients with indolent ATL with lymphadenopathy, which represents suspected signs of disease progression and/or transformation; lymph node biopsy is usually performed for accurate diagnosis. In these patients, histologically proven ATL-involved lymphadenopathy or other ATL lesions (pleural effusion, ascites or involvement of CNS, bone, gastrointestinal tract, liver or spleen) are required for diagnosis of acute-type ATL.
Diagnostic imaging plays a critical role in clinical staging and evaluation of efficacy in patients with malignant lymphoma [3, 4] . In particular, [ 18 F] 2-fluoro-
2-deoxyglucose (FDG)-positron emission tomography (PET) provides considerable information relative to
other imaging modalities such as CT and 67 Ga scintigraphy. FDG-PET is widely used to predict prognosis in solid malignancies including lung, and head and neck carcinomas [5] . FDG uptake in aggressive nonHodgkin's lymphoma (NHL) is significantly higher than in indolent lymphoma, and standardized uptake values (SUV) are helpful in distinguishing between indolent and aggressive NHL [6] . Furthermore, recent improvements in FDG-PET/CT software allow measurement of disease burden indicators, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) [5, 7] . MTV is measured by a semiautomatic software with an automatic iso-contour threshold algorithm. TLG is also a volume-based parameter, shown to be a promising prognostic index in various malignancies including malignant lymphoma [8, 9] . However, intensive analyses of FDG-PET in ATL patients have not been fully reported.
The purpose of the present study was to explore the potential relationship between malignant grade and analytical values as assessed using PET/CT volumetric techniques including SUV, MTV and TLG.
Materials and methods
Patients
Twenty-eight patients diagnosed with ATL (nine with smoldering or chronic, and 19 with lymphoma or acute types) were enrolled. All patients underwent skin (n = 14) or lymph node (n = 6) biopsies or hematological diagnosis from peripheral blood (n = 13). Patients received 18 F-FDG PET/CT between July 2013
and November 2015. Evaluation of clinical stage included complete blood count, biochemistry, chest X-ray, CT scans of the neck, chest and abdomen, FDG-PET/CT, and bone marrow examination. The present study was approved by the institutional review board at our university hospital (approval number 800), and all participants gave written informed consent.
FDG-PET and image analysis
A PET/CT scanner (Biograph mCT, Siemens Healthcare, Erlangen, Germany) with time-of-flight (TOF) was used in the present study. The image analysis was performed using a workstation with syngo-via software (Siemens Healthcare, Erlangen, Germany [10] was defined as the average SUV within a small, fixed-size region of interest (ROIpeak) centered on a high-uptake region of the tumor. Values of maximum SUV (SUVmax) and TLG with two variable margin thresholds were also acquired for analysis. TLG of a target lesion was calculated as the mean SUV (SUVmean) × MTV, which considers both the metabolic activity and tumor burden. SUVmean was measured by setting margin thresholds of 25%, and 50% of SUVmax for each lesion, resulting in SUVmean-25%, and SUVmean-50%, respectively. MTV was also measured by setting the margin thresholds as 25%, and 50% of SUVmax for each lesion, resulting in TLG-25% and TLG-50%, respectively. We estimated the MTV using a threshold method based on 25%, and 50% of SUVmax, as proposed by Ceriani et al. [11] and by Boellard et al. [12] for evaluation of tumoral lesions. On a patient basis, SUVmax was defined as the highest SUVmax among those for all lesions, and TLG for a patient was defined as the sum of all those lesions.
Statistical analysis
Between-group differences in PET parameters were evaluated using Fisher's exact test and Student's ttest as appropriate. Two sided P values <0.05 were considered as significant. All statistical analyses were performed using EZR (Saitama Medical Centre, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 2.13.0). More precisely, it is a modified version of R commander (version 1.27) that was designed to add statistical functions frequently used in biostatistics [13] . Receiver-operating characteristic (ROC) analyses were undertaken to assess the utility of PET/CT parameters for stratifying malignancy grade. Optimal cut-off values were identified by determining the values where the sum of sensitivity and specificity was maximal. Two nuclear medicine radiologists (Y.A. and M.O.) assessed the presence or absence of each lesion (qualitative analysis). Inter-observer agreement on FDG-PET/CT findings were analyzed using weighted κ statistics, defined as poor (κ < 0.2), fair (0.2 < κ ≤ 0.4), moderate (0.4 < κ ≤ 0.6), good (0.6 < κ ≤ 0.8), and very good (0.8 < κ ≤ 1) [14] . These analyses were performed for all nodal regions.
Results
Characteristics of patients studied
The clinical and pathologic characteristics of the 28 patients with ATL are shown in Table 1 . Each patient's ATL subtype was determined according to Shimoyama criteria [1] , which are internationally accepted for classification of ATL subtype. All patients with aggressive ATL (lymphoma 7, acute-type 12) underwent FDG-PET/CT scans prior to chemotherapy. Patients with indolent ATL (smoldering 6, chronic 3) underwent at the time of suspected disease progression and/or transformation. Among them, two patients underwent FDG-PET/CT scans when they relapsed. One patient with the chronic type received chemotherapy at 4 months before PET/CT, and another patient with the acute type received umbilical-cord blood transplantation at 6 months before PET/CT. The median age was 63.5 (range, 37-81) years with a male:female ratio of 1:1. Nineteen of the 28 patients had aggressive ATL (lymphoma, acute). Twenty of the 28 patients had a low performance status score (0-1). Twenty-six patients were categorized as being at an advanced clinical stage (III-IV). In 12 patients, FDG-PET/CT was performed from the top of the skull to the upper thigh. In the other patients, FDG-PET/CT was performed from the top of the skull to sole of the feet. All the nine patients with indolent ATL underwent FDG-PET/CT at a time when they showed lymphadenopathy; this is a suspected sign of disease progression and/or transformation. Lymph node biopsy was performed in six of these patients; however, pathological findings were HTLV-I associated lymphadenitis or dermatopathic lymphadenitis, which were reactive disorders [15, 16] .
Parameters for glucose metabolism in all lesions
A representative patient with indolent ATL exhibited low accumulation of FDG (Figure 1) , whereas a representative patient with aggressive ATL showed apparently higher accumulation of FDG (Figure 2 ). The median PET/CT parameters of all target lesions before treatment or at the time of suspected disease progression are listed in Table 2 . FDG-avid lesions and parameters in each patient are detailed in Table 3 . All patients except one showed FDG uptake in lymph nodes, and some had FDG-avid extra-nodal lesions such as in the spleen, skin, bone and liver. Patient 22 had chronic-type ATL, with higher SUVmax and 50% TLG than the rest of the indolent group, and showed systemic lymphadenopathy, splenomegaly, fever and liver dysfunction. A lymph node biopsy showed reactive lymphadenitis. As this patient was suspected of having chronic active Epstein-Barr virus infection (CAEBV) because of high peripheral levels of anti-EBV VCA-IgG, EBV-EA IgG, and EBV-DNA in peripheral blood, we considered that high FDG accumulation in this patient might reflect CAEBV activity [17] .
All of the pertinent parameter values for aggressive ATL were significantly higher than those for indolent ATL (Table 4 ). In patients with indolent ATL, FDG accumulation of the chronic type was higher than that of the smoldering type, albeit that there was no statistical difference (Table 2) . ROC analyses were performed to evaluate the usefulness of each PET/CT parameter in discriminating malignant grade. The AUC in ROC analysis of SUV, MTV and TLG ranged from 0.75 to 0.9, indicating high accuracy (Table 5) . 
Inter-observer agreement
The two nuclear medicine radiologists' inter-observer agreement for presence or absence of lesions shown by FDG-PET/CT is detailed in Table 6 . The κ value for all nodal regions was 0.97, indicating good inter-observer agreement (κ > 0.4). Their κ values for individual nodal regions were also satisfactory.
Discussion
The present study demonstrated that the PET/CT parameters (SUV, MTV and TLG) investigated were useful predictors of grade of malignant tumor in ATL patients. We analyzed the clinical utility of PET/CT parameters in distinguishing indolent ATL from aggressive ATL. A series of PET/CT parameter values (SUVmax, SUVpeak, SUVmean-25%, SUVmean-50%, MTV-25%, MTV-50%, TLG-25% and TLG-50%) for aggressive ATL were significantly higher than those for indolent ATL. It was also demonstrated that the AUC for these PET/CT parameters ranged from 0.75 to 0.92, indicating high accuracy in distinguishing indolent ATL from aggressive ATL. These results demonstrate that a series of PET/ CT parameters other than SUVmax are also clinicallyuseful parameters comparable to SUVmax in evaluating the malignancy grade of ATL. Our results also clearly demonstrated that overall inter-observer agreement between FDG-PET/CT findings was excellent. In FDG-PET/CT, FDG uptake and subsequent hypermetabolism of glucose is a reliable surrogate marker of aggressive biology in solid tumors and lymphomas [4, 18] . SUV has been used as a quantitative parameter for glucose metabolism, and SUVmax for a tumor lesion has been widely used as a survival predictor or in the grading of several solid tumors and some lymphomas [5, 8, 9] . However, it should be noted that SUVmax reflects the metabolic activities of the most aggressive cells, which does not necessarily align with the prognostic index. In some malignancies, TLG has recently been suggested as being a better metabolic parameter than SUVmax in FDG-PET/CT because TLG reflects the metabolic tumor burden [7] . Among a variety of malignant lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma show a high level of FDG uptake, indicating representative 'FDG-avid lymphomas' [3] . In contrast, other studies have demonstrated lower rates of PET detection for cutaneous T-cell lymphoma and extra-nodal marginal zone lymphoma [19] . However, there have been very few reports concerning FDG-PET studies on ATL [20] [21] [22] [23] [24] [25] .
ATL is notably characterized by multiple tumor lesions, which indicate a large tumor burden leading to multiple-organ failure [1] . We therefore hypothesized that TLG could help evaluate tumor burden and extent in ATL patients. The present study suggests that TLG, which reflects total metabolic tumor volume, also reflects aggressiveness and SUVmax in ATL (Table 5 ). MTV and TLG are immediately measured after ROI placement on the lesion by PET software, and facilitate measurement of lesion volume. As expected, our data demonstrates that both the intensity of FDG uptake and metabolic volume were significantly lower in the indolent type relative to the aggressive type (Table 4) , even though all the patients with the indolent type underwent FDG-PET/CT at the time when we suspected disease progression and/or transformation in these patients. We could not compare advantages of TLG with other FDG-PET parameters in the current study due to the relatively few subjects. Further studies with larger cohorts are required, both to verify our findings, and to elucidate the usefulness of TLG in predicting prognosis and aggressive transformation in patients with ATL. We also used PET-CT to optimize selection of biopsy sites in patients with suspected disease transformation, by targeting lymph nodes with the highest SUVmax values. It should be noted that there was concordance between low FDG/PET parameter values and no malignant pathological findings from lymph node biopsy. These findings suggest that low positive FDG/PET parameters in indolent ATL patients with lymphadenopathy might predict that it is not a sign of disease transformation from indolent type to aggressive type, but rather a reactive manifestation.
In the present study, we endeavored to optimize the margin threshold for both MTV and TLG measurements. It is widely accepted that the optimal margin threshold has not been established [11, 12] . Therefore, we assessed two margin thresholds, 25 and 50%. There was no difference in margin thresholds between 25 and 50% except for the MTV-25% (Tables 4 and 5 ). In calculating MTV, a high threshold tends to underestimate tumor burden, and a low threshold tends to overestimate tumor burden. The present study had some limitations. First, analytical methods may fail to detect malignancyassociated FDG accumulation in skin lesions, peripheral blood and intestine lesions, partly because physiological or pathophysiological accumulation independent of malignancies may interfere; in addition, very small lesions may be below the limits of spatial resolution. Even though skin invasion by ATL was proven by biopsy, FDG uptake would not be detected in some cases. In the present study, 14 of 28 patients had skin lesions. Although their PET images were negative, skin lesions were proven by biopsy in 7 of 14 patients with skin lesions. It is therefore possible that a falsenegative would be attributed to the flatness of the lesions as well as to earlier disease stage. Second, the number of ATL patients in this study was not large. We therefore could not ascertain optimal cut-off values for PET/CT parameters to differentiate between aggressive and indolent ATL types. Further studies with larger study cohorts are needed to verify and enlarge on our findings, particularly the relationship between FDG-PET/CT parameters and prognosis among aggressive ATLs.
Third, although patients in whom ATL was suspected to have transformed from indolent to aggressive type underwent FDG-PET/CT, their uptake was low, which suggests that FDG uptake in indolent types may be reactive.
Fourth, due to the small number of patients, FDG PET/CT parameters overlapped at the lower end of the aggressive group and the upper end of the indolent group.
In summary, the present study showed some PET-CT parameters -SUV, MTV, and TLG -were accurate indicators of malignancy grade in patients with ATL; and that related FDG-PET parameters can potentially indicate need and optimal biopsy site for patients in whom ATL progression or transformation is suspected.
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